Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Darbepoetin Alfa→

Darbepoetin Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
209810-58-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Erythropoiesis-stimulating AgentErythropoietinIncreased Erythroid Cell Production
Mechanism of action
Aranesp stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.
Indications / reported uses
  • Anemia
  • anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis
  • anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Darbepoetin Alfa Environmental Risk Assessment (ERA) (the Darbepoetin Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.